Improving CAR T cell therapy for Hodgkin Lymphoma
Official title: Tailoring CAR T cell therapy for Hodgkin Lymphoma
Funded at Univ of North Carolina Chapel Hill · NIH-10866397 · Data updated 2026-11-12
This study is testing a new treatment for people with Hodgkin Lymphoma that uses specially modified immune cells to better find and attack cancer cells, and it's designed for those whose cancer has come back or hasn't responded to other treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | July 1, 2020 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $599,281 |
| NIH project number | 5R01CA247497-05 |
| Project ID | NIH-10866397 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with relapsed or refractory Hodgkin Lymphoma or other CD30+ malignancies.
✕Less likely to help
Patients with CD30-negative malignancies or those who are not relapsed or refractory may not benefit from this research.
What this research studies
This research focuses on enhancing CAR T cell therapy specifically for patients with Hodgkin Lymphoma and other CD30+ malignancies. The approach involves engineering T cells to express a chimeric antigen receptor (CAR) that targets the CD30 antigen, combined with a chemokine receptor to improve the T cells' ability to migrate to tumors. A phase I clinical trial will be conducted to assess the safety and effectiveness of this therapy in patients with relapsed or refractory Hodgkin Lymphoma. Patients will be monitored for immune responses and tumor interactions to better understand the therapy's impact.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Hodgkin Lymphoma, potentially increasing the chances of complete remission.
How similar studies have gone: Previous studies have shown promise with CAR T cell therapies in similar contexts, indicating potential for success in this novel approach.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Savoldo, Barbara — Univ of North Carolina Chapel Hill
- Study coordinator: Savoldo, Barbara
Related research
Other NIH-funded projects on the same topics.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Trajectories of Neurotoxicity in young Hodgkin lymphoma patients
Aging Hodgkin lymphoma patients who are adolescents or young adults may face long-lasting brain and nerve-related side effects from their cancer treatment, and this study aims to map how those problems develop over time.
-
CD2-targeted CAR-T therapy for T-cell lymphoma in a multi-center program
A patient-focused overview of a research grant that aims to improve CAR-T cell therapy for T-cell lymphoma by exploring CD2 as a new target and enhancing allogeneic CAR-T safety features.
-
Combination therapy approach for non-Hodgkin lymphoma (NHL)
A Mayo Clinic team is testing a new combination treatment for non-Hodgkin lymphoma to improve responses in patients and in dogs with similar disease.
-
Multi-antigen T cell therapy for relapsed NHL
A patient-derived T cell therapy called MT-601 targets six tumor-associated antigens to help treat relapsed non-Hodgkin lymphoma after other therapies may have failed.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.